PDCD1 and neoplasm: Avelumab is a fully human monoclonal antibody that inhibits the interaction between programmed death-ligand 1 (PD-L1) on tumor cells and programmed cell death protein 1 (PD-1) on T cells, thus reducing immunosuppression in the tumor microenvironment and slowing tumor growth.